NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Not Allowed)
ID: 351693Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/351693

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-24-102.html
Timeline
    Description

    The National Institutes of Health (NIH) is inviting applications for the NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01), aimed at supporting high-risk, multi-center observational studies that focus on diseases relevant to the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Applicants are required to complete a planning phase prior to submission and must include a Plan for Enhancing Diverse Perspectives (PEDP) to promote inclusivity in their research. This funding opportunity is crucial for advancing clinical research in areas such as diabetes and related conditions, while also addressing health disparities and fostering community engagement. The application window is open from January 5, 2024, to November 5, 2026, with inquiries directed to NIH Grants Information at grantsinfo@nih.gov. For more details, applicants can refer to the full announcement available at https://grants.nih.gov/grants/guide/pa-files/PAR-24-102.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-24-102-Full-Announcement.html
    PAR-24-102.html
    The National Institutes of Health (NIH) seeks applications for high-risk, multi-center observational studies under the NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01). This funding opportunity promotes investigator-initiated studies targeting diseases aligned with the NIDDK’s mission, including diabetes and related conditions. Applicants must complete a planning phase before applying for the U01 award and provide a Plan for Enhancing Diverse Perspectives (PEDP) that promotes inclusivity throughout the study. The application process emphasizes rigorous study design and adherence to NIH data management policies. Key dates include application submissions from January 5, 2024, to November 5, 2026, with rigorous review criteria focused on scientific significance, innovation, and the applicant's ability to conduct the research. Eligible institutions include higher education entities, non-profits, and government organizations. NIH aims to address health disparities by encouraging studies involving underrepresented groups and fostering community engagement. Applications that do not align with these guidelines or lack necessary documentation will be deemed incomplete. This initiative reflects the NIH's commitment to advancing clinical research within its designated health domains while enhancing diversity and equity in healthcare research.
    Similar Opportunities
    NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01), aimed at supporting investigator-initiated, high-risk clinical trials that involve multiple clinical centers. Applicants must propose hypothesis-driven studies that focus on diseases relevant to the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), with an emphasis on enhancing diverse perspectives in research. This funding opportunity is crucial for advancing therapeutic studies that can significantly improve clinical practices and public health outcomes. Interested applicants should note that the application period opens on January 5, 2024, with a closing date of November 5, 2026, and are encouraged to consult with NIDDK staff prior to submission. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), is offering a funding opportunity for high-risk multi-center clinical study implementation planning via Cooperative Agreements (U34). This initiative aims to support the early peer review of proposed clinical studies, assess study designs, and develop essential documentation, including operational manuals, focusing on diseases relevant to NIDDK's mission. The program emphasizes health equity and inclusivity, requiring a Plan for Enhancing Diverse Perspectives (PEDP) as part of the application. Interested applicants can apply for up to $225,000 per year for a maximum of two years, with the application submission period opening on September 9, 2024, and the closing date set for June 10, 2027. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov.
    High Impact, Interdisciplinary Science in NIDDK Research Areas (RC2 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "High Impact, Interdisciplinary Science in NIDDK Research Areas (RC2 Clinical Trial Optional)" aimed at supporting innovative research that addresses significant knowledge gaps within the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). This initiative encourages interdisciplinary approaches to foster advancements in understanding, treating, and preventing diseases related to diabetes, digestive, and kidney disorders, with a focus on generating impactful research resources and hypothesis-generating science. Eligible applicants include a wide range of institutions such as higher education entities, nonprofits, for-profits, and various governmental agencies, with project durations extending up to five years initially and a total funding period of up to ten years. Interested parties should note that the application deadline is October 30, 2024, and are encouraged to contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    NIDDK Education Program Grants (R25 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), is offering Research Education Program Grants (R25) to enhance training in biomedical, behavioral, and clinical research. This funding opportunity aims to support educational activities that develop research skills and provide hands-on experiences in areas critical to NIDDK, including diabetes, digestive diseases, and obesity. Eligible applicants include a wide range of organizations such as higher education institutions, non-profits, and local governments, with a funding limit of $100,000 per year for up to five years. The application deadline is January 30, 2024, and interested parties can find more information by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the program's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-074.html.
    Small R01s for Clinical Trials Targeting Diseases within the Mission of NIDDK (R01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for small Research Project Grants (R01s) aimed at clinical trials focused on diseases under the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). This initiative encourages the submission of pilot and feasibility clinical trials that will provide foundational data for larger, definitive trials intended to improve the prevention and treatment of various health conditions, without the requirement of preliminary efficacy data. The program supports innovative research ideas and emphasizes equitable recruitment from diverse populations, with a maximum grant duration of three years and funding up to $200,000 per year. Interested applicants can find more information and submit their applications by May 7, 2026, and should direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Early-Stage Preclinical Validation of Therapeutic Leads for Diseases of Interest to the NIDDK (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Early-Stage Preclinical Validation of Therapeutic Leads for Diseases of Interest to the NIDDK (R01 Clinical Trial Not Allowed)." This grant aims to support translational research that justifies later-phase therapeutic discovery and development efforts related to diseases such as obesity, diabetes, digestive disorders, and kidney diseases. The initiative encourages innovative research on novel small molecules and biologics, with a focus on therapeutics that significantly improve or differentiate from existing treatments. NIH anticipates awarding 3-4 grants annually, with budgets ranging from $250,000 to $300,000 per project for up to five years. Interested applicants must submit their proposals by January 7, 2025, and can reach out to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries. Additional details can be found at http://grants.nih.gov/grants/guide/pa-files/PAR-22-111.html.
    Priority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Priority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional)" to stimulate research aligned with the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). This initiative aims to support research on HIV-related comorbidities, gastrointestinal diseases, and metabolic disorders associated with HIV, encouraging applications from a diverse range of organizations, including higher education institutions and non-profits. With an estimated funding of $2 million for fiscal year 2025, the NIH plans to support 3 to 5 selected projects over a maximum project period of five years, with applications undergoing a rigorous peer review process. Interested applicants can find more information and submit their proposals through Grants.gov, with a submission deadline of January 7, 2025. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Limited Competition for the Continuation of Type 1 Diabetes in Acute Pancreatitis Consortium - Clinical Centers (T1DAPC-CCs) (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a Limited Competition Funding Opportunity titled "Continuation of Type 1 Diabetes in Acute Pancreatitis Consortium - Clinical Centers" (T1DAPC-CCs), aimed at establishing a clinical consortium to study diabetes incidence following acute pancreatitis episodes, with a focus on type 1 diabetes. This initiative seeks applications from previously funded Clinical Centers to continue a longitudinal observational study that investigates the incidence, etiology, and risk factors associated with diabetes emerging after acute pancreatitis, emphasizing collaboration among consortium members and effective data collection strategies. The funding amount is capped at $350,000 annually, with a project timeline extending up to five years, and applications are due by November 19, 2024, with the earliest anticipated award start in July 2025. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Single Source for the Continuation of the Type 1 Diabetes in Acute Pancreatitis Consortium - Data Coordinating Center (T1DAPC-DCC) (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is soliciting applications for a cooperative agreement to establish the Type 1 Diabetes in Acute Pancreatitis Consortium Data Coordinating Center (T1DAPC-DCC). The primary objective is to conduct a longitudinal observational study, known as the DREAM study, which will investigate the incidence and mechanisms of diabetes that develop following episodes of acute pancreatitis. This initiative is crucial for understanding the relationship between acute pancreatitis and the onset of diabetes, particularly type 1 diabetes, and aims to identify genetic and environmental risk factors in a diverse population. Interested applicants must submit their proposals by November 19, 2024, with a funding ceiling of $800,000, and can direct inquiries to grantsinfo@nih.gov for further information.
    Type 1 Diabetes TrialNet Clinical Network Hub (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for the Type 1 Diabetes TrialNet Clinical Network Hub (HUB), aimed at enhancing clinical trials focused on the prevention and early intervention of Type 1 Diabetes (T1D). The HUB will coordinate operations across various clinical centers to improve participant screening, recruitment, and retention, with a specific emphasis on increasing diversity among participants, particularly from minority populations. This initiative is critical for addressing the rising incidence of T1D and ensuring inclusivity in research efforts. The funding opportunity has an estimated budget of $750,000 per year from a total allocation of $1,000,000, with a maximum project duration of five years. Applications will be accepted starting September 16, 2024, and must include a Plan for Enhancing Diverse Perspectives (PEDP) to be considered complete. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.